* KALA BIO Inc reported a quarterly adjusted loss of $1.93 per share for the quarter , higher than the same quarter last year, when the company reported EPS of $-3.41. The mean expectation of two analysts for the quarter was for a loss of $2.43 per share. Wall Street expected results to range from $-2.71 to $-2.15 per share.
* Reported revenue was zero; analysts expected zero.
* KALA BIO Inc's reported EPS for the quarter was a loss of $1.93.
* The company reported a quarterly loss of $8.95 million.
* KALA BIO Inc shares had risen by 29.8% this quarter and gained 5.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 31% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for KALA BIO Inc is $15.00 This summary was machine generated from LSEG data November 12 at 03:26 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.43 -1.93 Beat
Jun. 30 2024 -4.40 -3.16 Beat
Mar. 31 2024 -2.89 -4.19 Missed
Dec. 31 2023 -3.62 -3.18 Beat
Comments